# Tyler Shultz says AI is reviving the Theranos playbook

Published 2026-10-30T16:24:14+00:00 · Updated 2026-10-30T16:24:14+00:00 · By superintelligencenews@gmail.com
Canonical: https://superintelligencenews.com/applications/ai-boom-fraud-theranos-whistleblower-warning/

> Tyler Shultz says the AI boom is making it easier for founders to deceive investors, and he warns that Theranos-era lessons are being forgotten. TechCrunch reports he sees weak due diligence, flashy demos and founder-driven hype as a dangerous repeat pattern.

## Key facts

- Theranos reached a peak valuation near $10 billion before its blood-testing claims collapsed, according to TechCrunch.
- Tyler Shultz says AI startups are harder to diligence because investors may not be able to verify product claims from the outside.
- TechCrunch reports that Haemanthus, a diagnostics startup linked to Elizabeth Holmes and Billy Evans, has raised about $20 million.
- Elizabeth Holmes is serving a federal prison sentence of over 11 years.
- Shultz said, “I think the days of having a thirty-minute coffee with someone and sending them $100,000 should be over.”

Tyler Shultz, the Theranos whistleblower, says the AI boom is making it easier for founders to mislead investors, and he argues the industry is already forgetting the lessons of one of Silicon Valley’s most notorious frauds. In an interview highlighted by TechCrunch, Shultz warned that shaky due diligence and polished demos can let founders raise large sums long before their products are proved.

 

## Why it matters

 

Shultz’s warning lands at a moment when AI startups are attracting money quickly, often on the strength of a compelling pitch rather than a fully validated business. His concern is not just that some founders may exaggerate what their systems can do, but that investors may struggle to tell the difference between genuine innovation and what he called a “ChatGPT wrapper.”

 

That matters because the Theranos story was built on the same kind of asymmetry: charismatic founders, limited outside scrutiny, and investors eager to believe a breakthrough was close. Shultz says the structure of AI funding today can make the same dynamic easier to repeat.

 

## What Tyler Shultz is warning about

 

Shultz’s core point is simple: AI products can be hard to evaluate from the outside, which gives dishonest founders more room to operate. According to TechCrunch, he said due diligence is especially difficult in AI because buyers and investors may not be able to verify whether a product actually works as advertised.

 

He framed the risk in blunt terms: if a startup is mostly packaging an existing model, a slick demo and a strong story may be enough to raise capital before reality catches up. In his view, that makes AI a new venue for deception rather than a category immune to it.

 

> “If you want to deceive people, I think this is a great opportunity to go deceive people.”

 

Shultz also argued that investors need to stop treating quick introductory meetings as sufficient proof of merit. TechCrunch reported that he used the example of a short coffee meeting leading to a fast investment decision, something he says should no longer happen in the AI era.

 

> “I think the days of having a thirty-minute coffee with someone and sending them $100,000 should be over.”

 

## How the Theranos lesson fits into the AI boom

 

Theranos remains the clearest modern example of a company that raised money on a powerful narrative while its core technology failed to deliver. TechCrunch reported that the blood-testing startup reached a peak valuation near $10 billion even though its technology never actually worked as claimed.

 

According to the report, Theranos used its own machines for only a fraction of tests and outsourced others to third-party equipment. Its devices also reached Walgreens and produced faulty results for patients, which helped expose the gap between the company’s claims and the reality behind them.

 

Shultz’s point is that the fundraising pattern mattered as much as the product claims. Theranos raised money from wealthy individual investors, including members of the DeVos and Walton families, while also failing to satisfy some top Silicon Valley venture firms that wanted stronger evidence. TechCrunch reported that the company withheld scientific evidence from potential investors, citing trade-secret concerns, which made independent verification even harder.

 

That is the pattern Shultz fears could repeat in AI: a founder sells the story before the evidence is clear, and the market rewards momentum before validation.

 

## Background: how we got here

 

Shultz became one of the key whistleblowers in the Theranos saga after working at the company early in his career. The Theranos story later collapsed into criminal and regulatory consequences for founder Elizabeth Holmes, who was convicted and is now serving a federal prison sentence of over 11 years.

 

TechCrunch described the case as closed, but not forgotten. Holmes’s name has returned to the spotlight because of the documentary *You Can See Everything*, which renewed attention on her and on the broader culture around Theranos. The report says Holmes and Billy Evans are shown working on a new diagnostics startup called Haemanthus, a company some have dubbed “Theranos 2.0.”

 

That revival is exactly what unsettles Shultz. He told TechCrunch that Holmes appears to be preparing what he called a “second act,” suggesting that her public re-emergence is not accidental and may be part of a larger effort to re-enter the startup world.

 

## Why AI startups are especially hard to judge

 

AI companies often face a credibility gap because their products can look impressive in a demo while the underlying system remains uncertain, expensive, or limited in practice. Shultz’s warning is that this gap can be exploited by founders who know how to package a believable story around incomplete technology.

 

Unlike hardware or regulated diagnostics, many AI products are difficult for outsiders to inspect. Investors may see a polished interface, hear a compelling narrative, and still have little way to test whether the system actually performs as claimed in a live environment. That makes due diligence more important, not less.

 

Shultz’s message is aimed squarely at investors who assume the market will self-correct quickly. His argument is that by the time the correction arrives, large sums may already be committed and reputational damage may already be done.

 

### What investors should be asking

 

Shultz’s comments imply a more skeptical checklist for AI funding decisions. The core question is whether the company can prove performance beyond a demo or a carefully controlled presentation.

 

- What, exactly, does the product do without manual intervention?
- Can the underlying system be verified by independent experts?
- Is the startup creating new capability or mostly repackaging existing tools?
- Are claims backed by data that outside investors can inspect?
- Does the company depend on trust in the founder more than proof in the product?

 

## Theranos-era fundraising and the power of the story

 

One reason the Theranos comparison remains potent is that the company did not rely only on institutional venture capital. TechCrunch reported that Holmes scaled a model of winning trust from wealthy individual backers and expanded it to massive sums, turning a small-circle fundraising pitch into a broader capital-raising machine.

 

Shultz says that pattern is what he sees as most dangerous today. The modern AI market rewards speed, and speed can disguise weak foundations. When investors move on a short timeline, founders can use narrative, hype, and selective product access to fill in the gaps.

 

The issue is not that every AI startup is deceptive. The issue is that the market’s appetite for the next major platform makes it easier for the dishonest few to blend in with the legitimate majority.

 

| Theranos and AI warning signs | Theranos | AI boom, per Shultz |
| --- | --- | --- |
| Valuation pressure | Peak valuation near $10 billion | Large sums raised before products are fully proven |
| Investor access | Wealthy individual investors, including DeVos and Walton family members | Founders can still win money quickly with a strong pitch |
| Verification problem | Scientific evidence withheld from investors | Due diligence is harder because AI outputs are difficult to validate externally |
| Product proof | Machines never actually worked as claimed | Investors may not distinguish real innovation from a “ChatGPT wrapper” |
| Public fallout | Faulty results reached patients through Walgreens | Shultz warns the cost of weak diligence can be severe if deception is missed early |

 

## What Holmes’s reported “second act” changes

 

Holmes’s prison sentence does not mean the public conversation around Theranos is finished. If anything, the reporting on Haemanthus and the documentary attention around Holmes suggest the opposite: her name still draws interest, and that attention may create a new audience for future ventures.

 

For Shultz, that is part of the problem. He appears to believe Holmes’s visibility risks turning a closed fraud case into a kind of playbook, especially if the market treats her reappearance as another story of comeback rather than a warning.

 

TechCrunch reported that Holmes and Evans are working on Haemanthus, a diagnostics startup said to have raised about $20 million. The company’s exact technology remains unclear from the fact sheet, but the reporting itself is enough to reignite concern about whether the same trust-heavy fundraising dynamics are returning under a new name.

 

## What happens next

 

The biggest open question is simple: what is Haemanthus actually building, and can its technology be independently validated? That answer will shape whether the startup is treated as a serious diagnostics effort or as another case study in hype outrunning proof.

 

Another question is whether investors in AI will change their behavior. Shultz’s comments suggest that stronger diligence is overdue, but the market has not yet shown a broad shift away from quick decisions and charismatic founder bets.

 

The documentary *You Can See Everything* may also keep Holmes in public view, which could influence how people interpret any future startup activity connected to her. If Holmes steps back into the spotlight, the reaction may reveal whether Silicon Valley has absorbed the Theranos lesson or simply filed it away.

 

For now, Shultz is arguing that the industry is at a fork in the road. One path leads to sharper scrutiny, slower capital, and more proof. The other repeats a familiar sequence: a persuasive story, a rushed check, and a reckoning that comes too late.

 

## By the numbers

 

These figures capture the scale of the Theranos story and the concerns now surrounding its possible echo in AI.

 

| Metric | Figure | Context |
| --- | --- | --- |
| Theranos peak valuation | $10 billion | The company’s highest reported value before its claims fell apart |
| Common investor meeting example | 30-minute coffee | Shultz’s shorthand for overly casual diligence |
| Example check size | $100,000 | The amount he says investors could send after a short meeting |
| Holmes prison sentence | Over 11 years | The sentence she is serving in federal prison |
| Haemanthus funding reported | $20 million | Amount the startup is said to have raised |

 

## The larger lesson for founders and investors

 

Shultz’s warning is less about one disgraced founder than about a recurring market failure. When a technology is difficult to understand, easy to demo, and expensive to verify, the temptation to believe a good story can overwhelm the discipline required to test it.

 

That is why the Theranos comparison remains so powerful in the AI era. It is not just that one startup failed. It is that the failure showed how quickly trust, money, and prestige can stack on top of incomplete evidence.

 

If the AI sector wants to avoid the same outcome, Shultz is arguing that it will need more than better branding and louder promises. It will need patience, skepticism, and proof that survives contact with reality.

## Frequently asked questions

### Why is Tyler Shultz warning about AI startups?

Tyler Shultz is warning that AI startups can be easier to overstate than to verify, creating room for founders to mislead investors. He says the same trust-heavy dynamics that enabled Theranos could reappear in a market where products are hard to independently test.

### What did Tyler Shultz say about investor diligence?

Tyler Shultz said investors should not make fast funding decisions based on short meetings and trust alone. He argued that AI due diligence is especially difficult, which makes it more important for investors to demand hard proof before committing money.

### What was the Theranos lesson Shultz is referring to?

The Theranos lesson is that a company can raise huge sums on a persuasive story even when the core technology does not work. TechCrunch reported that Theranos reached a near-$10 billion valuation while its blood-testing system failed to deliver reliable results.

### What is Haemanthus?

Haemanthus is a diagnostics startup reportedly being built by Elizabeth Holmes and Billy Evans. TechCrunch says it has raised about $20 million, but the fact sheet does not establish what exactly the company is building or whether its technology has been validated.

### Is Elizabeth Holmes back in business?

The report says Holmes is in federal prison, but renewed attention from a documentary and reporting on Haemanthus suggests she may be preparing a return of some kind. Shultz said he believes she is beginning a “second act,” though where it leads is unclear.

## Sources

- [TechCrunch](https://techcrunch.com/2026/10/30/theranos-whistleblower-tyler-shultz-warns-that-the-ai-boom-is-a-great-opportunity-to-go-deceive-people/)